Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single-center study.
chemoradiotherapy
cisplatin
docetaxel
ear cancer
fluorouracil
temporal bone
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
30
05
2023
received:
13
03
2023
accepted:
23
06
2023
medline:
25
9
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Squamous cell carcinoma of the external auditory canal (EACSCC) is a rare condition. However, a standard treatment has not yet been established. We retrospectively evaluated the efficacy, adverse events, and feasibility of TPF-CCRT (concomitant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced EACSCC. Thirty-five consecutive patients with advanced EACSCC (T3, T4) initially treated with TPF-CCRT at Kobe University Hospital were included. T4 diseases with invasion of the brain, internal carotid artery, or internal jugular vein were classified as T4b, and those without these features were classified as T4a. Five-year overall survival rates for T3 and T4 were 100% and 64.2%, respectively. A significant difference was observed between T4a and T4b (82.4% vs. 30%, p = 0.007). Five-year progression-free survival rates of T3, T4a, and T4b were 100%, 68%, and 20% (p = 0.022), respectively. TPF-CCRT should be considered as a plausible treatment option for advanced EACSCC.
Sections du résumé
BACKGROUND
Squamous cell carcinoma of the external auditory canal (EACSCC) is a rare condition. However, a standard treatment has not yet been established. We retrospectively evaluated the efficacy, adverse events, and feasibility of TPF-CCRT (concomitant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced EACSCC.
METHODS
Thirty-five consecutive patients with advanced EACSCC (T3, T4) initially treated with TPF-CCRT at Kobe University Hospital were included. T4 diseases with invasion of the brain, internal carotid artery, or internal jugular vein were classified as T4b, and those without these features were classified as T4a.
RESULTS
Five-year overall survival rates for T3 and T4 were 100% and 64.2%, respectively. A significant difference was observed between T4a and T4b (82.4% vs. 30%, p = 0.007). Five-year progression-free survival rates of T3, T4a, and T4b were 100%, 68%, and 20% (p = 0.022), respectively.
CONCLUSIONS
TPF-CCRT should be considered as a plausible treatment option for advanced EACSCC.
Substances chimiques
Docetaxel
15H5577CQD
Fluorouracil
U3P01618RT
Cisplatin
Q20Q21Q62J
Taxoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2498-2504Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Morlon RP, Stell PM, Derrick PP. Epidemiology of cancer of the middle ear cleft. Cancer. 1984;53:1612-1617.
Shinomiya H, Uehara N, Teshima M, Kakigi A, Otsuki N, Nibu KI. Clinical management for T1 and T2 external auditory canal cancer. Auris Nasus Larynx. 2019;46(5):785-789.
Shiga K, Nibu KI, Fujimoto Y, et al. Multi-institutional survey of squamous cell carcinoma of the external auditory canal in Japan. Laryngoscope. 2021;131(3):E870-E874.
Shinomiya H, Hasegawa S, Yamashita D, et al. Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone. Head Neck. 2016;38(Suppl 1):E949-E953.
Shiga K, Ogawa T, Maki A, Amano M, Kobayashi T. Concomitant chemoradiotherapy as a standard treatment for squamous cell carcinoma of the temporal bone. Skull Base. 2011;21:153-158.
Komatsu M, Shiono O, Taguchi T, et al. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol. 2014;44(5):416-421.
Tsukuda M, Ishitoya J, Matsuda H, et al. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2010;66(4):729-736.
Moody SA, Hirsch BE, Myers EN. Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol. 2000;21:582-588.
Shinomiya H, Uehara N, Fujita T, et al. New proposal to revise the classification for squamous cell carcinoma of the external auditory canal and middle ear. J Laryngol Otol. 2021;135(4):297-303.
Nabuurs CH, Kievit W, Leemans CR, et al. Evaluation of subclasses for T4-classified squamous cell carcinoma of the external auditory canal. Head Neck. 2022;44(8):1787-1798.
Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873-898.
Cheung PK, Chin RY, Eslick GD. Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2016;154(3):421-432.
Griffiths EA, Roy V, Alwan L, et al. NCCN guidelines® insights: hematopoietic growth factors, version 2.2023. J Natl Compr Canc Netw. 2023;20(5):436-442.
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-3212.
Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1(1):CD004386.
Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-1704.
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-1715.
Shinomiya H, Uehara N, Fujita T, et al. Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF-CRT) for locally advanced squamous cell carcinoma of the external auditory canal. Eur Arch Otorhinolaryngol. 2022;279(6):2805-2810.
McCloskey SA, Jaggernauth W, Rigual NR, et al. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009;32(6):587-591.
Patel UA, Patadia MO, Holloway N, Rosen F. Poor radiotherapy compliance predicts persistent regional disease in advanced head/neck cancer. Laryngoscope. 2009;119(3):528-533.
Moffat DA, Wagstaff SA, Hardy DG. The outcome of radical surgery and postoperative radiotherapy for squamous carcinoma of the temporal bone. Laryngoscope. 2005;115(2):341-347.
Yin M, Ishikawa K, Honda K, et al. Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx. 2006;33(3):251-257.
Madsen AR, Gundgaard MG, Hoff CM, et al. Cancer of the external auditory canal and middle ear in Denmark from 1992 to 2001. Head Neck. 2008;30(10):1332-1338.
Takenaka Y, Cho H, Nakahara S, Yamamoto Y, Yasui T, Inohara H. Chemoradiation therapy for squamous cell carcinoma of the external auditory canal: a meta-analysis. Head Neck. 2015;37(7):1073-1080.
Morita S, Homma A, Nakamaru Y, et al. The outcomes of surgery and chemoradiotherapy for temporal bone cancer. Otol Neurotol. 2016;37(8):1174-1182.